<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:npr="https://www.npr.org/rss/" xmlns:nprml="https://api.npr.org/nprml" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>NPR: COVID booster</title>
    <link>https://www.npr.org/templates/story/story.php?storyId=1049194495</link>
    <description>COVID booster</description>
    <language>en</language>
    <copyright>Copyright 2024 NPR - For Personal Use Only</copyright>
    <generator>Story API Shim 1.2.24</generator>
    <lastBuildDate>Wed, 07 May 2025 00:14:51 -0400</lastBuildDate>
    <image>
      <url>https://media.npr.org/images/podcasts/primary/npr_generic_image_300.jpg?s=200</url>
      <title>NPR: COVID booster</title>
      <link>https://www.npr.org/tags/1049194495/covid-booster</link>
    </image>
    <item>
      <title>Economics, boosternomics and Swiftnomics</title>
      <description>For this week&apos;s Indicators of the Week, Darian is joined by NPR colleagues Jeff Guo and Sydney Lupkin. We get into the &lt;a href=&quot;https://www.census.gov/library/publications/2023/demo/p60-280.html&quot;&gt;latest numbers on child poverty in the U.S.&lt;/a&gt; and what it tells us about effective policy intervention. Sydney brings an update on the new covid booster and who&apos;s paying for it. And Jeff talks about Taylor Swift...again. He promises it has to do with economics.&lt;br&gt;&lt;br&gt;&lt;em&gt;For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at &lt;/em&gt;&lt;a href=&quot;http://plus.npr.org/&quot;&gt;&lt;em&gt;plus.npr.org&lt;/em&gt;&lt;/a&gt;&lt;em&gt;.&lt;br&gt;&lt;br&gt;Music by &lt;/em&gt;&lt;a href=&quot;https://dropelectric.bandcamp.com/&quot;&gt;&lt;em&gt;Drop Electric&lt;/em&gt;&lt;/a&gt;&lt;em&gt;. Find us: &lt;/em&gt;&lt;a href=&quot;https://www.tiktok.com/@planetmoney&quot;&gt;&lt;em&gt;TikTok&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.instagram.com/planetmoney/&quot;&gt;&lt;em&gt;Instagram&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.facebook.com/planetmoney&quot;&gt;&lt;em&gt;Facebook&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.npr.org/newsletter/money&quot;&gt;&lt;em&gt;Newsletter&lt;/em&gt;&lt;/a&gt;&lt;em&gt;.&lt;/em&gt;</description>
      <pubDate>Fri, 15 Sep 2023 18:53:36 -0400</pubDate>
      <link>https://www.npr.org/2023/09/15/1197954124/economics-boosternomics-and-swiftnomics</link>
      <guid>https://www.npr.org/2023/09/15/1197954124/economics-boosternomics-and-swiftnomics</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/09/15/gettyimages-1474302749-54f942abc145dc2d7701d8b8e29cb92ff4841370.jpg' alt='undefined'/><p>For this week's Indicators of the Week, Darian is joined by NPR colleagues Jeff Guo and Sydney Lupkin. We get into the <a href="https://www.census.gov/library/publications/2023/demo/p60-280.html">latest numbers on child poverty in the U.S.</a> and what it tells us about effective policy intervention. Sydney brings an update on the new covid booster and who's paying for it. And Jeff talks about Taylor Swift...again. He promises it has to do with economics.<br><br><em>For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at </em><a href="http://plus.npr.org/"><em>plus.npr.org</em></a><em>.<br><br>Music by </em><a href="https://dropelectric.bandcamp.com/"><em>Drop Electric</em></a><em>. Find us: </em><a href="https://www.tiktok.com/@planetmoney"><em>TikTok</em></a>, <a href="https://www.instagram.com/planetmoney/"><em>Instagram</em></a>, <a href="https://www.facebook.com/planetmoney"><em>Facebook</em></a>, <a href="https://www.npr.org/newsletter/money"><em>Newsletter</em></a><em>.</em></p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1197954124' />]]></content:encoded>
      <dc:creator>Darian Woods</dc:creator>
    </item>
    <item>
      <title>FDA advisers back updated COVID shots for fall vaccinations</title>
      <description>A panel of advisers to the Food and Drug Administration has recommended revising the current COVID-19 vaccine so that it specifically targets omicron.</description>
      <pubDate>Thu, 15 Jun 2023 16:21:52 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/06/15/1182503195/fda-advisers-back-updated-covid-shots-for-fall-vaccinations</link>
      <guid>https://www.npr.org/sections/health-shots/2023/06/15/1182503195/fda-advisers-back-updated-covid-shots-for-fall-vaccinations</guid>
      <content:encoded><![CDATA[<p>A panel of advisers to the Food and Drug Administration has recommended revising the current COVID-19 vaccine so that it specifically targets omicron.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1182503195' />]]></content:encoded>
      <dc:creator>Pien Huang</dc:creator>
    </item>
    <item>
      <title>COVID test kits, treatments and vaccines won&apos;t be free to many consumers much longer</title>
      <description>Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you&apos;ll pay depends on your health insurance.</description>
      <pubDate>Wed, 08 Feb 2023 05:00:33 -0500</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/02/08/1155225903/covid-test-kits-treatments-vaccines-increasing-cost-to-consumers</link>
      <guid>https://www.npr.org/sections/health-shots/2023/02/08/1155225903/covid-test-kits-treatments-vaccines-increasing-cost-to-consumers</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/02/07/gettyimages-1360580571-1--7f981a2c4b8c7d0dee5044ce824abed42594d621.jpg' alt='Starting May 11 most people will have to pay for those at-home test kits for COVID-19, as the federal government's declaration of a COVID-19 public health emergency officially ends.'/><p>Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you'll pay depends on your health insurance.</p><p>(Image credit: Alex Wong)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1155225903' />]]></content:encoded>
      <dc:creator>Julie Appleby</dc:creator>
    </item>
    <item>
      <title>An FDA committee votes to roll out a new COVID vaccination strategy</title>
      <description>Advisers to the U.S. Food and Drug Administration today endorsed a proposal to make big changes in the nation&apos;s approach to vaccinating people against COVID-19.</description>
      <pubDate>Thu, 26 Jan 2023 16:42:38 -0500</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/01/26/1151810765/fda-committee-votes-to-roll-out-new-covid-vaccination-strategy</link>
      <guid>https://www.npr.org/sections/health-shots/2023/01/26/1151810765/fda-committee-votes-to-roll-out-new-covid-vaccination-strategy</guid>
      <content:encoded><![CDATA[<p>Advisers to the U.S. Food and Drug Administration today endorsed a proposal to make big changes in the nation's approach to vaccinating people against COVID-19.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1151810765' />]]></content:encoded>
      <dc:creator>Scott Hensley</dc:creator>
    </item>
    <item>
      <title>The FDA considers a major shift in the nation&apos;s COVID vaccine strategy</title>
      <description>The new approach would simplify vaccination guidance so that, every fall, people would get a new shot, updated to try to match whatever variant is dominant.</description>
      <pubDate>Mon, 23 Jan 2023 05:00:00 -0500</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/01/23/1150032238/fda-considers-major-shift-in-covid-vaccine-strategy</link>
      <guid>https://www.npr.org/sections/health-shots/2023/01/23/1150032238/fda-considers-major-shift-in-covid-vaccine-strategy</guid>
      <content:encoded><![CDATA[<p>The new approach would simplify vaccination guidance so that, every fall, people would get a new shot, updated to try to match whatever variant is dominant.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1150032238' />]]></content:encoded>
      <dc:creator>Rob Stein</dc:creator>
    </item>
    <item>
      <title>CDC recommends new booster shots to fight omicron</title>
      <description>CDC Director Rochelle Walensky has signed off on  updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.</description>
      <pubDate>Thu, 01 Sep 2022 17:50:50 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/09/01/1120560488/cdc-advisers-back-new-booster-shots-to-fight-omicron</link>
      <guid>https://www.npr.org/sections/health-shots/2022/09/01/1120560488/cdc-advisers-back-new-booster-shots-to-fight-omicron</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/09/01/pfizer-covid-19-ba4.5-vaccine_vials-2_custom-35b8a0d12bdbc12184b832690028ae51f6251fc4.jpg' alt='Vials of the reformulated Pfizer-BioNTech COVID-19 booster move through production at a plant in Kalamazoo, Mich.'/><p>CDC Director Rochelle Walensky has signed off on  updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1120560488' />]]></content:encoded>
      <dc:creator>Jane Greenhalgh</dc:creator>
    </item>
    <item>
      <title>Summer boosters for people under 50 shelved in favor of updated boosters in the fall</title>
      <description>The Biden administration is scrapping plans to offer COVID boosters for people under 50 this summer. Instead officials will push for an earlier release of the next generation boosters in the fall.</description>
      <pubDate>Thu, 28 Jul 2022 22:57:00 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/07/28/1114408611/summer-boosters-for-people-under-50-shelved-in-favor-of-updated-boosters-in-the</link>
      <guid>https://www.npr.org/sections/health-shots/2022/07/28/1114408611/summer-boosters-for-people-under-50-shelved-in-favor-of-updated-boosters-in-the</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/07/28/gettyimages-1363332361_custom-0d70cb3ef9882a4612cf6cc3cedea2b0460cb4c6.jpg' alt='The Biden administration plans to offer updated booster shots in the fall.'/><p>The Biden administration is scrapping plans to offer COVID boosters for people under 50 this summer. Instead officials will push for an earlier release of the next generation boosters in the fall.</p><p>(Image credit: Mario Tama)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1114408611' />]]></content:encoded>
      <dc:creator>Rob Stein</dc:creator>
    </item>
    <item>
      <title>FDA authorizes first COVID booster for children ages 5 to 11</title>
      <description>The Food and Drug Administration expanded authorization of Pfizer-BioNTech&apos;s COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.</description>
      <pubDate>Tue, 17 May 2022 10:45:00 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2022/05/17/1099442330/fda-authorizes-first-covid-booster-for-children-ages-5-to-11</link>
      <guid>https://www.npr.org/sections/health-shots/2022/05/17/1099442330/fda-authorizes-first-covid-booster-for-children-ages-5-to-11</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/05/17/gettyimages-1352926961-92d2a476bb862c2bb2e17d096cc7aa2746b6e855.jpg' alt='First grader Rihanna Chihuaque, 7, receives a COVID-19 vaccine at Arturo Velasquez Institute in Chicago last November.'/><p>The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.</p><p>(Image credit: Scott Olson)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1099442330' />]]></content:encoded>
      <dc:creator>Rob Stein</dc:creator>
    </item>
    <item>
      <title>When To Consider Another COVID-19 Booster</title>
      <description>This week, U.S. Food and Drug Administration vaccine advisors will meet to discuss long-term COVID vaccine strategy. This follows the recent FDA authorization and CDC recommendation of a second booster available for people 50 and older and some immunocompromised people. Going forward, will the strategy change from counting boosters to making a COVID vaccine a seasonal shot? Allison Aubrey talks to Emily Kwong about the latest on boosters, what&apos;s known about the vaccination timeline for younger children, and what some experts are saying about the BA.2 variant.</description>
      <pubDate>Tue, 05 Apr 2022 00:15:52 -0400</pubDate>
      <link>https://www.npr.org/2022/04/04/1090944428/when-to-consider-another-covid-19-booster</link>
      <guid>https://www.npr.org/2022/04/04/1090944428/when-to-consider-another-covid-19-booster</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2022/04/04/gettyimages-1239624136-79bae1741cb92485e912dce7d81475e14d75237f.jpg' alt='US President Joe Biden receives a second booster shot of the Pfizer Covid-19 vaccine a day after the US authorized a fourth dose of either the Pfizer-BioNTech or Moderna Covid-19 vaccines for people 50 and older'/><p>This week, U.S. Food and Drug Administration vaccine advisors will meet to discuss long-term COVID vaccine strategy. This follows the recent FDA authorization and CDC recommendation of a second booster available for people 50 and older and some immunocompromised people. Going forward, will the strategy change from counting boosters to making a COVID vaccine a seasonal shot? Allison Aubrey talks to Emily Kwong about the latest on boosters, what's known about the vaccination timeline for younger children, and what some experts are saying about the BA.2 variant.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1090944428' />]]></content:encoded>
      <dc:creator>Allison Aubrey</dc:creator>
    </item>
    <item>
      <title>FDA shortens the wait time between Moderna vaccine and booster to 5 months</title>
      <description>Now, both the Pfizer and the Moderna booster shots can be given five months after the second dose of vaccine — down from six months.</description>
      <pubDate>Fri, 07 Jan 2022 11:35:45 -0500</pubDate>
      <link>https://www.npr.org/sections/coronavirus-live-updates/2022/01/07/1071249854/fda-shortens-the-wait-time-between-moderna-vaccine-and-booster-to-5-months</link>
      <guid>https://www.npr.org/sections/coronavirus-live-updates/2022/01/07/1071249854/fda-shortens-the-wait-time-between-moderna-vaccine-and-booster-to-5-months</guid>
      <content:encoded><![CDATA[<p>Now, both the Pfizer and the Moderna booster shots can be given five months after the second dose of vaccine — down from six months.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1071249854' />]]></content:encoded>
      <dc:creator>Deepa Shivaram</dc:creator>
    </item>
  </channel>
</rss>